{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T09:35:40Z","timestamp":1774517740798,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T00:00:00Z","timestamp":1733616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Nivolumab obtained approval in advanced melanoma (AM) with weight\u2010adjusted dose (WAD) administration (3 mg\/kg\/2 weeks). In 2018, the dosage regimen was changed to flat dose (FD) administration (240 mg\/2 weeks or 480 mg\/4 weeks) based on a modeling study, without clinical data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>AM patients have been prospectively included in the French national multicenter MelBase database since 2013. First\u2010line patients treated with nivolumab monotherapy were included in the WAD or FD groups of this study. The primary end point was the incidence of grade \u22653 immune\u2010related adverse events (irAEs). Secondary end points were incidence of any grade irAEs, and overall survival (OS) and progression\u2010free survival (PFS). Inverse probability of treatment weighting was used to balance groups on their baseline characteristics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between 2015 and 2022, 348 patients were included: 160 in the WAD and 188 in the FD groups. In the FD group, 45% and 27% of patients weighed &lt;75 kg and &gt;85 kg, respectively. Grade \u22653 and any grade irAEs rates were 13.1% versus 11.7% (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.8) and 63.1% versus 67.0% (<jats:italic>p<\/jats:italic>\u00a0=\u00a0.5) in the WAD and FD groups, respectively. After weighting, median PFS was 3.1 and 3.7 months (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.65\u20131.07), and median OS was 24.8 and 37.0 months (HR, 0.74; 95% CI, 0.54\u20131.01) in the WAD and FD groups, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There was no difference in the incidence of severe irAEs and in median PFS between AM patients treated by WAD or FD nivolumab. The median OS between patient groups did not reach statistical significance.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.35679","type":"journal-article","created":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T04:01:21Z","timestamp":1733630481000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Methods of nivolumab administration in advanced melanoma: A comparison of patients\u2019 clinical outcomes treated with flat dose or weight\u2010adjusted dose, a multicenter observational study"],"prefix":"10.1002","volume":"131","author":[{"given":"Iona Campo","family":"Le Brun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Henri Mondor Hospital Assistance Publique\u2013H\u00f4pitaux de Paris  Cr\u00e9teil France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[{"name":"INSERM 1052 Department of Dermatology Hospices Civils de Lyon Lyon\u2010Sud hospital Pierre\u2010Benite Lyon University Claude Bernard Lyon 1 University CNRS 5286 L\u00e9on B\u00e9rard center Cancer Research Center of Lyon  Lyon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[{"name":"INSERM U1189 Department of Dermatology Lille University Hospital Universit\u00e9 de Lille  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Dereure","sequence":"additional","affiliation":[{"name":"INSERM U1058, Department of Dermatology University of Montpellier  Montpellier France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie Dalac","family":"Rat","sequence":"additional","affiliation":[{"name":"Department of Dermatology Dijon Bourgogne University Hospital  Dijon France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Dutriaux","sequence":"additional","affiliation":[{"name":"Department of Dermatology Saint Andr\u00e9 Hospital  Bordeaux France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Th\u00e9r\u00e8se","family":"Leccia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Allergology, Photobiology Grenoble Alpes University Hospital  La Tronche France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Legoupil","sequence":"additional","affiliation":[{"name":"Department of Dermatology Brest University Regional Hospital  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[{"name":"INSERM U1065 Department of Dermatology Nice University Hospital L\u2019Archet Hospital  Nice France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"De Quatrebarbes","sequence":"additional","affiliation":[{"name":"Department of Dermatology Annecy Genevois Hospital  Epagny Metz\u2010Tessy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Gaudy\u2010Marqueste","sequence":"additional","affiliation":[{"name":"Dermatology and Skin Cancer Department Aix\u2010Marseille University Assitance Publique des Hopitaux de Marseille La Timone Hospital  Marseille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[{"name":"Department of Dermatology Avicenne Hospital  Bobigny France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[{"name":"Department of General and Oncology Dermatology Ambroise Par\u00e9 Hospital University Paris\u2010Saclay Assistance Publique\u2013H\u00f4pitaux de Paris  Boulogne\u2010Billancourt France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pag\u00e8s","sequence":"additional","affiliation":[{"name":"Department of Onco\u2010Dermatology University Cancer Institute\u2010Oncopole  Toulouse France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence Brunet","family":"Possenti","sequence":"additional","affiliation":[{"name":"Department of Dermatology Bichat\u2010Claude\u2010Bernard Hospital Assistance Publique\u2013H\u00f4pitaux de Paris  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Granel\u2010Brocard","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nancy University Regional Hospital Brabois Hospitals  Vand\u0153uvre\u2010l\u00e8s\u2010Nancy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00ebl","family":"Porcher","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Cit\u00e9 and Universit\u00e9 Sorbonne Paris Nord Inserm INRAE Center for Research in Epidemiology and Statistics (CRESS) Centre d'\u00c9pid\u00e9miologie Clinique Assistance Publique\u2013H\u00f4pitaux de Paris H\u00f4pital H\u00f4tel Dieu  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Lefevre","sequence":"additional","affiliation":[{"name":"Saint Louis Hospital Assistance Publique\u2013H\u00f4pitaux de Paris MELBASE  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-7290","authenticated-orcid":false,"given":"C\u00e9l\u00e8ste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"INSERM U976 Universit\u00e9 Paris Cit\u00e9 Assistance Publique\u2013H\u00f4pitaux de Paris Dermato\u2010Oncology and CIC Cancer Institute APHP nord Paris Cit\u00e9 Saint Louis Hospital  Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9285-1966","authenticated-orcid":false,"given":"Emmanuelle","family":"Kempf","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Henri Mondor Hospital Assistance Publique\u2013H\u00f4pitaux de Paris  Cr\u00e9teil France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,12,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1003466"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010021\u201001182\u20103"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1412082"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200690"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.0105"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.0703"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy408"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx235"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220918019"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.02.016"},{"key":"e_1_2_9_12_1","unstructured":"US Department of Health and Human Services.Common Terminology Criteria for Adverse Events (CTCAE)Version 4.0.2009. Accessed December 4 2024.https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/Archive\/CTCAE_4.0_2009\u201005\u201029_QuickReference_8.5x11.pdf"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(17)30074\u20108"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/cmr.0000000000000132"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001885"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(22)00554\u2010x"},{"key":"e_1_2_9_17_1","unstructured":"The Business Research Company.Checkpoint Inhibitors Global Market Report 2023. Accessed May 26 2023.https:\/\/www.researchandmarkets.com\/reports\/5733882\/checkpoint\u2010inhibitors\u2010global\u2010market\u2010report"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109970"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33467"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1709030"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab064"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.01015"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113392"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425\u2010017\u20100242\u20105"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw174"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12406"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.982"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.875"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2023.00102"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i788"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2888"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219833743"},{"key":"e_1_2_9_33_1","unstructured":"Summary \u2010 Update of the tool for choosing the dosage of monoclonal antibodies targeting PD 1 or PD\u2010L1. Accessed December 4 2024.https:\/\/www.inesss.qc.ca\/en\/publications\/publications\/publication\/posologie\u2010des\u2010anticorps\u2010monoclonaux\u2010ciblant\u2010le\u2010pd\u20101\u2010ou\u2010le\u2010pd\u2010l1.html"},{"key":"e_1_2_9_34_1","unstructured":"CancerCare Manitoba.Consensus recommendations for management of malignant melanoma. Accessed October 6 2023.https:\/\/ext\u2010opencms.cancercare.mb.ca\/export\/sites\/default\/For\u2010Health\u2010Professionals\/.galleries\/files\/treatment\u2010guidelines\u2010rro\u2010files\/practice\u2010guidelines\/cutaneous\/DM_Consensus_Recommendations_for_Management_of_Malignant_Melanoma_June\u20101\u20102016.pdf"},{"key":"e_1_2_9_35_1","volume-title":"Cancer Protocol Summary for the Treatment of Unresectable or Metastatic Melanoma Using Ipilimumab and Nivolumab","author":"Bernstein V","year":"2023"},{"key":"e_1_2_9_36_1","unstructured":"SwetterSM BichakjianC DiMaioD GalanA KiuruM SmithE.NCCN Guidelines Index Table of Contents Discussion.2023. Accessed December 4 2024.https:\/\/www.nccn.org\/docs\/default\u2010source\/about\/annual\u2010report\u20102023.pdf?sfvrsn=8411082_31"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.35679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:59:08Z","timestamp":1760266748000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.35679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/cncr.35679"],"URL":"https:\/\/doi.org\/10.1002\/cncr.35679","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,8]]},"assertion":[{"value":"2024-08-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e35679"}}